1887

Abstract

Shigella are ranked among the most prevalent aetiologies of diarrhoeal disease worldwide, disproportionately affecting young children in developing countries and high-risk communities in developed settings. Antimicrobial treatment, most commonly with fluoroquinolones, is currently recommended for Shigella infections to alleviate symptoms and control disease transmission. Resistance to fluoroquinolones has emerged in differing Shigella species (S. dysenteriae, flexneri and sonnei) since the turn of the 21st century, originating in endemic areas, and latterly spreading into non-endemic regions. Despite occurring independently, the emergence of fluoroquinolone resistance in these different Shigella species shares striking similarities regarding their epidemiology and resistance mechanisms. Here, we review and discuss the current epidemiology of fluoroquinolone-resistant Shigella species, particularly in the light of recent genomic insights.

Loading

Article metrics loading...

/content/journal/mgen/10.1099/mgen.0.000171
2018-03-29
2020-01-29
Loading full text...

Full text loading...

/deliver/fulltext/mgen/4/4/mgen000171.html?itemId=/content/journal/mgen/10.1099/mgen.0.000171&mimeType=html&fmt=ahah

References

  1. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013;382:209–222 [CrossRef][PubMed]
    [Google Scholar]
  2. Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A et al. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017;17:909–948 [CrossRef][PubMed]
    [Google Scholar]
  3. Bardhan P, Faruque AS, Naheed A, Sack DA. Decrease in shigellosis-related deaths without Shigella spp.-specific interventions, Asia. Emerg Infect Dis 2010;16:1718–1723 [CrossRef][PubMed]
    [Google Scholar]
  4. Sahl JW, Morris CR, Emberger J, Fraser CM, Ochieng JB et al. Defining the phylogenomics of Shigella species: a pathway to diagnostics. J Clin Microbiol 2015;53:951–960 [CrossRef][PubMed]
    [Google Scholar]
  5. Chung The H, Thanh DP, Holt KE, Thomson NR, Baker S. The genomic signatures of Shigella evolution, adaptation and geographical spread. Nat Rev Microbiol 2016;14:235–250 [CrossRef][PubMed]
    [Google Scholar]
  6. Shiga K. Ueber den erreger der dysenterie in Japan (vorläufige mitteilung). Zentralbl Bakteriol Mikrobiol 1898;23:599–600
    [Google Scholar]
  7. Pal SC. Epidemic bacillary dysentery in West Bengal, India, 1984. The Lancet 1984;323:1462 [CrossRef]
    [Google Scholar]
  8. Barceloux DG. Shigella species (Shiga Enterotoxins). In Medical Toxicology of Natural Substances Hoboken, New Jersey, USA: John Wiley & Sons, Inc; 2008; pp.150–155
    [Google Scholar]
  9. Gu B, Cao Y, Pan S, Zhuang L, Yu R et al. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009. Int J Antimicrob Agents 2012;40:9–17 [CrossRef][PubMed]
    [Google Scholar]
  10. Vinh H, Wain J, Chinh MT, Tam CT, Trang PT et al. Treatment of bacillary dysentery in Vietnamese children: two doses of ofloxacin versus 5-days nalidixic acid. Trans R Soc Trop Med Hyg 2000;94:323–326 [CrossRef][PubMed]
    [Google Scholar]
  11. WHO Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. World Health Organization 2005
  12. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 2014;22:438–445 [CrossRef][PubMed]
    [Google Scholar]
  13. Kahsay AG, Muthupandian S. A review on Sero diversity and antimicrobial resistance patterns of Shigella species in Africa, Asia and South America, 2001–2014. BMC Res Notes 2016;9:422 [CrossRef][PubMed]
    [Google Scholar]
  14. Tamanna, Ramana J. Structural insights into the fluoroquinolone resistance mechanism of Shigella flexneri DNA gyrase and topoisomerase IV. Microb Drug Resist 2016;22:404–411 [CrossRef][PubMed]
    [Google Scholar]
  15. Tacconelli E, Magrini N, Kahlmeter G, Singh N. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Heal Organ 2017;1–7
    [Google Scholar]
  16. Bhattacharya SK, Sarkar K, Balakrish Nair G, Faruque AS, Sack DA. Multidrug-resistant Shigella dysenteriae type 1 in south Asia. Lancet Infect Dis 2003;3:755 [CrossRef][PubMed]
    [Google Scholar]
  17. Naheed A, Kalluri P, Talukder KA, Faruque AS, Khatun F et al. Fluoroquinolone-resistant Shigella dysenteriae type 1 in northeastern Bangladesh. Lancet Infect Dis 2004;4:607–608 [CrossRef][PubMed]
    [Google Scholar]
  18. Pazhani GP, Sarkar B, Ramamurthy T, Bhattacharya SK, Takeda Y et al. Clonal multidrug-resistant Shigella dysenteriae type 1 strains associated with epidemic and sporadic dysenteries in eastern India. Antimicrob Agents Chemother 2004;48:681–684 [CrossRef][PubMed]
    [Google Scholar]
  19. Talukder KA, Khajanchi BK, Islam MA, Dutta DK, Islam Z et al. Genetic relatedness of ciprofloxacin-resistant Shigella dysenteriae type 1 strains isolated in south Asia. J Antimicrob Chemother 2004;54:730–734 [CrossRef][PubMed]
    [Google Scholar]
  20. Taneja N. Changing epidemiology of shigellosis and emergence of ciprofloxacin-resistant Shigellae in India. J Clin Microbiol 2007;45:678–679 [CrossRef][PubMed]
    [Google Scholar]
  21. Njamkepo E, Fawal N, Tran-Dien A, Hawkey J, Strockbine N et al. Global phylogeography and evolutionary history of Shigella dysenteriae type 1. Nat Microbiol 2016;1:16027 [CrossRef][PubMed]
    [Google Scholar]
  22. Azmi IJ, Khajanchi BK, Akter F, Hasan TN, Shahnaij M et al. Fluoroquinolone resistance mechanisms of Shigella flexneri isolated in Bangladesh. PLoS One 2014;9:e102533 [CrossRef][PubMed]
    [Google Scholar]
  23. Wang XY, Du L, von Seidlein L, Xu ZY, Zhang YL et al. Occurrence of shigellosis in the young and elderly in rural China: results of a 12-month population-based surveillance study. Am J Trop Med Hyg 2005;73:416–422[PubMed]
    [Google Scholar]
  24. Qin T, Bi R, Fan W, Kang H, Ma P et al. Novel mutations in quinolone resistance-determining regions of gyrA, gyrB, parC and parE in Shigella flexneri clinical isolates from eastern Chinese populations between 2001 and 2011. Eur J Clin Microbiol Infect Dis 2016;35:2037–2045 [CrossRef][PubMed]
    [Google Scholar]
  25. Nüesch-Inderbinen M, Heini N, Zurfluh K, Althaus D, Hächler H et al. Shigella antimicrobial drug resistance mechanisms, 2004–2014. Emerg Infect Dis 2016;22:1083–1085 [CrossRef][PubMed]
    [Google Scholar]
  26. Zhang J, Jin H, Hu J, Yuan Z, Shi W et al. Antimicrobial resistance of Shigella spp. from humans in Shanghai, China, 2004–2011. Diagn Microbiol Infect Dis 2014;78:282–286 [CrossRef][PubMed]
    [Google Scholar]
  27. Qiu S, Xu X, Wang Y, Yang G, Wang Z et al. Emergence of resistance to fluoroquinolones and third-generation cephalosporins in Shigella flexneri subserotype 1c isolates from China. Clin Microbiol Infect 2012;18:E95E98 [CrossRef][PubMed]
    [Google Scholar]
  28. Cui X, Wang J, Yang C, Liang B, Ma Q et al. Prevalence and antimicrobial resistance of Shigella flexneri serotype 2 variant in China. Front Microbiol 2015;6:435 [CrossRef][PubMed]
    [Google Scholar]
  29. Pu XY, Pan JC, Wang HQ, Zhang W, Huang ZC et al. Characterization of fluoroquinolone-resistant Shigella flexneri in Hangzhou area of China. J Antimicrob Chemother 2009;63:917–920 [CrossRef][PubMed]
    [Google Scholar]
  30. Zhang W, Luo Y, Li J, Lin L, Ma Y et al. Wide dissemination of multidrug-resistant Shigella isolates in China. J Antimicrob Chemother 2011;66:2527–2535 [CrossRef][PubMed]
    [Google Scholar]
  31. Qin T, Qian H, Fan W, Ma P, Zhou L et al. Newest data on fluoroquinolone resistance mechanism of Shigella flexneri isolates in Jiangsu Province of China. Antimicrob Resist Infect Control 2017;6:1–8 [CrossRef][PubMed]
    [Google Scholar]
  32. Connor TR, Barker CR, Baker KS, Weill FX, Talukder KA et al. Species-wide whole genome sequencing reveals historical global spread and recent local persistence in Shigella flexneri. Elife 2015;4:1–16 [CrossRef][PubMed]
    [Google Scholar]
  33. Zhang N, Lan R, Sun Q, Wang J, Wang Y et al. Genomic portrait of the evolution and epidemic spread of a recently emerged multidrug-resistant Shigella flexneri clone in China. J Clin Microbiol 2014;52:1119–1126 [CrossRef][PubMed]
    [Google Scholar]
  34. Yang C, Li P, Zhang X, Ma Q, Cui X et al. Molecular characterization and analysis of high-level multidrug-resistance of Shigella flexneri serotype 4s strains from China. Sci Rep 2016;6:29124 [CrossRef][PubMed]
    [Google Scholar]
  35. Thompson CN, Duy PT, Baker S. The rising dominance of Shigella sonnei: an intercontinental shift in the etiology of bacillary dysentery. PLoS Negl Trop Dis 2015;9:e0003708 [CrossRef][PubMed]
    [Google Scholar]
  36. Ud-Din AI, Wahid SU, Latif HA, Shahnaij M, Akter M et al. Changing trends in the prevalence of Shigella species: emergence of multi-drug resistant Shigella sonnei biotype g in Bangladesh. PLoS One 2013;8:e82601 [CrossRef][PubMed]
    [Google Scholar]
  37. Qiu S, Xu X, Yang C, Wang J, Liang B et al. Shift in serotype distribution of Shigella species in China, 2003-2013. Clin Microbiol Infect 2015;21:252.e5–252.e8 [CrossRef]
    [Google Scholar]
  38. Bangtrakulnonth A, Vieira AR, Lo Fo Wong DM, Pornreongwong S, Pulsrikarn C et al. Shigella from humans in Thailand during 1993 to 2006: spatial-time trends in species and serotype distribution. Foodborne Pathog Dis 2008;5:773–784 [CrossRef][PubMed]
    [Google Scholar]
  39. Vinh H, Nhu NT, Nga TV, Duy PT, Campbell JI et al. A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentation. BMC Infect Dis 2009;9:204 [CrossRef][PubMed]
    [Google Scholar]
  40. De Lappe N, O'Connor J, Garvey P, Mckeown P, Cormican M. Ciprofloxacin-resistant Shigella sonnei associated with travel to India. Emerg Infect Dis 2015;21:894–896 [CrossRef][PubMed]
    [Google Scholar]
  41. Bowen A, Hurd J, Hoover C, Khachadourian Y, Traphagen E et al. Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin – United States, May 2014-February 2015. MMWR Morb Mortal Wkly Rep 2015;64:318–320[PubMed]
    [Google Scholar]
  42. Nandy S, Dutta S, Ghosh S, Ganai A, Rajahamsan J et al. Foodborne-associated Shigella sonnei, India, 2009 and 2010. Emerg Infect Dis 2011;17:2072–2073 [CrossRef][PubMed]
    [Google Scholar]
  43. Ghosh S, Pazhani GP, Chowdhury G, Guin S, Dutta S et al. Genetic characteristics and changing antimicrobial resistance among Shigella spp. isolated from hospitalized diarrhoeal patients in Kolkata, India. J Med Microbiol 2011;60:1460–1466 [CrossRef][PubMed]
    [Google Scholar]
  44. Ruekit S, Wangchuk S, Dorji T, Tshering KP, Pootong P et al. Molecular characterization and PCR-based replicon typing of multidrug resistant Shigella sonnei isolates from an outbreak in Thimphu, Bhutan. BMC Res Notes 2014;7:95–99 [CrossRef][PubMed]
    [Google Scholar]
  45. Chung The H, Rabaa MA, Pham Thanh D, De Lappe N, Cormican M et al. South Asia as a reservoir for the global spread of ciprofloxacin-resistant Shigella sonnei: a cross-sectional study. PLoS Med 2016;13:e1002055 [CrossRef][PubMed]
    [Google Scholar]
  46. Poramathikul K, Bodhidatta L, Chiek S, Oransathid W, Ruekit S et al. Multidrug-resistant Shigella infections in patients with diarrhea, Cambodia, 2014–2015. Emerg Infect Dis 2016;22:1640–1643 [CrossRef][PubMed]
    [Google Scholar]
  47. Kim JS, Kim JJ, Kim SJ, Jeon S, Seo KY et al. Shigella sonnei associated with travel to Vietnam, Republic of Korea. Emerg Infect Dis 2015;21:1247–1250
    [Google Scholar]
  48. Kozyreva VK, Jospin G, Greninger AL, Watt JP, Eisen JA et al. Recent outbreaks of Shigellosis in California caused by two distinct populations of Shigella sonnei with either increased virulence or fluoroquinolone resistance. mSphere 2016;1:e00344-16 [CrossRef][PubMed]
    [Google Scholar]
  49. Chung The H, Rabaa MA, Thanh DP, Ruekit S, Wangchuk S et al. Introduction and establishment of fluoroquinolone-resistant Shigella sonnei into Bhutan. Microb Genom 2015;1:1–11 [CrossRef][PubMed]
    [Google Scholar]
  50. Sadouki Z, Day MR, Doumith M, Chattaway MA, Dallman TJ et al. Comparison of phenotypic and WGS-derived antimicrobial resistance profiles of Shigella sonnei isolated from cases of diarrhoeal disease in England and Wales, 2015. J Antimicrob Chemother 2017;72:2496–2502 [CrossRef][PubMed]
    [Google Scholar]
  51. Das A, Natarajan M, Mandal J. The emergence of quinolone resistant Shigella sonnei, Pondicherry, India. PLoS One 2016;11:e0160290 [CrossRef][PubMed]
    [Google Scholar]
  52. Gaudreau C, Ratnayake R, Pilon PA, Gagnon S, Roger M et al. Ciprofloxacin-resistant Shigella sonnei among men who have sex with men, Canada, 2010. Emerg Infect Dis 2011;17:1747–1750 [CrossRef][PubMed]
    [Google Scholar]
  53. Chiou CS, Izumiya H, Kawamura M, Liao YS, Su YS et al. The worldwide spread of ciprofloxacin-resistant Shigella sonnei among HIV-infected men who have sex with men, Taiwan. Clin Microbiol Infect 2016;22:383.e11–383.e16 [CrossRef][PubMed]
    [Google Scholar]
  54. Mohan K, Hibbert M, Rooney G, Canvin M, Childs T et al. What is the overlap between HIV and shigellosis epidemics in England: further evidence of MSM transmission?. Sex Transm Infect 2018;94:67–71 [CrossRef][PubMed]
    [Google Scholar]
  55. Niyogi SK. Increasing antimicrobial resistance–an emerging problem in the treatment of shigellosis. Clin Microbiol Infect 2007;13:1141–1143 [CrossRef][PubMed]
    [Google Scholar]
  56. Kotwani A, Chaudhury RR, Holloway K. Antibiotic-prescribing practices of primary care prescribers for acute diarrhea in New Delhi, India. Value Health 2012;15:S116–S119 [CrossRef][PubMed]
    [Google Scholar]
  57. Marcusson LL, Frimodt-Møller N, Hughes D. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 2009;5:e1000541 [CrossRef][PubMed]
    [Google Scholar]
  58. Huseby DL, Pietsch F, Brandis G, Garoff L, Tegehall A et al. Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli. Mol Biol Evol 2017;34:1029–1039 [CrossRef][PubMed]
    [Google Scholar]
  59. Holt KE, Baker S, Weill FX, Holmes EC, Kitchen A et al. Shigella sonnei genome sequencing and phylogenetic analysis indicate recent global dissemination from Europe. Nat Genet 2012;44:1056–1059 [CrossRef][PubMed]
    [Google Scholar]
  60. World Bank 2015; World development indicators. Available fromhttps://data.worldbank.org/indicator/
  61. Laxminarayan R, Chaudhury RR. Antibiotic resistance in India: drivers and opportunities for action. PLoS Med 2016;13:e1001974 [CrossRef][PubMed]
    [Google Scholar]
  62. van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014;14:742–750 [CrossRef][PubMed]
    [Google Scholar]
  63. Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events. Nat Genet 2015;47:632–639 [CrossRef][PubMed]
    [Google Scholar]
  64. Baker S, Duy PT, Nga TV, Dung TT, Phat VV et al. Fitness benefits in fluoroquinolone-resistant Salmonella Typhi in the absence of antimicrobial pressure. Elife 2013;2:e01229 [CrossRef][PubMed]
    [Google Scholar]
  65. Fuzi M, Szabo D, Csercsik R. Double-serine fluoroquinolone resistance mutations advance major international clones and lineages of various multi-drug resistant bacteria. Front Microbiol 2017;8:1–14 [CrossRef][PubMed]
    [Google Scholar]
  66. Grad YH, Harris SR, Kirkcaldy RD, Green AG, Marks DS et al. Genomic epidemiology of gonococcal resistance to extended-spectrum cephalosporins, macrolides, and fluoroquinolones in the United States, 2000–2013. J Infect Dis 2016;214:1579–1587 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/mgen/10.1099/mgen.0.000171
Loading
/content/journal/mgen/10.1099/mgen.0.000171
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error